| Identification | Back Directory | [Name]
GANODERIC ACID A | [CAS]
81907-62-2 | [Synonyms]
(2R,6R)
Aids070759
Aids-070759
GANODERIC ACID A
GANODERIC ACID A(P)
Ganoderic acid A, >98%
-6-((7S,10S,13R,14R,15S,17R)
-2-methyl-4-oxoheptanoic acid
Ganoderic acid A, froM GanoderMa luciduM
(25R)-7β,15α-Dihydroxy-3,11,23-trioxo-5α-lanost-8-en-26-oicaci
(25R)-7β,15α-Dihydroxy-3,11,23-trioxo-5α-lanost-8-en-26-oic acid
Lanost-8-en-26-oic acid, 7,15-dihydroxy-3,11,23-trioxo-, (7β,15α,25R)-
(7beta,15alpha,25R)-7,15-Dihydroxy-3,11,23-trioxo-lanost-8-en-26-oic acid
Ganoderic acid A, 98%, from Micromeria biflora (Buch.-Ham. ex D. Don) Benth.
Lanost-8-en-26-oic acid, 7,15-dihydroxy-3,11,23-trioxo-, (7.beta.,15.alpha.,25R)-
-7,15-Dihydroxy-4,4,10,13,14-pentamethyl-3,11-dioxo-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)
(2R,6R)-6-[(5R,7S,10S,13R,14R,15S,17R)-7,15-dihydroxy-4,4,10,13,14-pentamethyl-3,11-dioxo-2,5,6,7,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid
(2R,6R)-6-((7S,10S,13R,14R,15S,17R)-7,15-Dihydroxy-4,4,10,13,14-pentaMethyl-3,11-dioxo-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-Methyl-4-oxoheptanoic acid | [Molecular Formula]
C30H44O7 | [MDL Number]
MFCD07779161 | [MOL File]
81907-62-2.mol | [Molecular Weight]
516.67 |
| Chemical Properties | Back Directory | [Melting point ]
118～123℃ | [Boiling point ]
690.1±55.0 °C(Predicted) | [density ]
1.22 | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
Chloroform (Slightly, Sonicated), Methanol (Slightly) | [form ]
Solid | [pka]
4.78±0.23(Predicted) | [color ]
White to Pale Yellow | [InChIKey]
OVUOUFPIPZJGME-YYJACZGBNA-N | [SMILES]
[C@@]12(C)[C@@H](O)C[C@H](/C(/C)=C/C(=O)CC(C)C(O)=O)[C@@]1(C)CC(=O)C1[C@@]3([C@]([H])(C(C)(C)C(CC3)=O)C[C@H](O)C2=1)C |&1:0,2,5,17,23,24,34,r| |
| Hazard Information | Back Directory | [Description]
Ganoderic acid A is a triterpene that has been found in Ganoderma and has diverse biological activities.1,2,3,4,5 It reduces cell viability, expression of superoxide dismutase 1 (SOD1), SOD2, and SOD3, and production of reactive oxygen species (ROS) in PC3 prostate cancer cells.1 Ganoderic acid A (2-100 μg/ml) reduces hypoxia-induced apoptosis in H9c2 cardiomyocytes.2 It inhibits LPS-induced activation of NF-κB, release of TNF-α, IL-1β, and IL-6, and mitochondrial activity in primary mouse cortical microglia.3 Ganoderic acid A (20 and 40 mg/kg) reduces lung myeloperoxidase (MPO) activity, neutrophil infiltration, and NF-κB signaling, as well as bronchoalveolar lavage fluid (BALF) levels of TNF-α, IL-1β, and IL-6 in a mouse model of LPS-induced lung injury.4 It also reduces weight gain and hepatic lipid accumulation and improves insulin sensitivity in a mouse model of high-fat diet-induced obesity.5 | [Chemical Properties]
White powder | [Uses]
Ganoderic Acid A, is a new lanostanoid triterpene extracted from the fruit bodies of Ganoderma Lucidum mushroom. these compounds are shown to possess many therapeutic properties. They can be used as anti-virus, anti-inflammation, anti-tumor, immunity-promoting, anti-diabetic, etc. | [Definition]
ChEBI: Ganoderic acid A is a triterpenoid. | [in vivo]
Ganoderic acid A treatment significantly prolonged survival of EL4 challenged mice and decreased tumor metastasis to the liver[4]. | [References]
[1] B. S. GILL N Sanjeev Kumar. Evaluating anti-oxidant potential of ganoderic acid A in STAT 3 pathway in prostate cancer[J]. Molecular Biology Reports, 2016, 43 1: 1411-1422. DOI: 10.1007/s11033-016-4074-z
[2] BAOJIN CHI. Effects of ganoderic acid A on lipopolysaccharide-induced proinflammatory cytokine release from primary mouse microglia cultures.[J]. Experimental and therapeutic medicine, 2018, 15 1: 847-853. DOI: 10.3892/etm.2017.5472
[3] BING WAN. Ganoderic acid A attenuates lipopolysaccharide-induced lung injury in mice.[J]. Bioscience Reports, 2019. DOI: 10.1042/bsr20190301
[4] JING ZHU . Ganoderic Acid A improves high fat diet-induced obesity, lipid accumulation and insulin sensitivity through regulating SREBP pathway[J]. Chemico-Biological Interactions, 2018, 290: Pages 77-87. DOI: 10.1016/j.cbi.2018.05.014 |
|
|